Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407209 | 1.00 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL2650423 | 0.89 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL26453747 | 0.87 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL246026 | 0.87 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL26453761 | 0.87 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL19354304 | 0.86 | TSHR (0.50) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL20466894 | 0.86 | TSHR (0.50) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL20863301 | 0.86 | TSHR (0.50) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL84441 | 0.85 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL4514218 | 0.84 | PTGS1 (0.51) | TSHRLOXL2CYP4F2CYP4A11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | TSHR 441/4885LOXL2 3539/4885CYP4F2 399/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | TSHR 265/4885LOXL2 2461/4885CYP4F2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.